Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

This was the stock's second consecutive day of losses.

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The fate of 23andMe (MEHCQ) and the treasure trove of data it has on its users is set to be fought over in court. Yahoo ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...